Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single implant replace the morning-after pill?

NCT ID NCT05237141

Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study tests whether inserting the etonogestrel contraceptive implant before ovulation can prevent pregnancy, potentially serving as emergency contraception. Twelve women with regular cycles will receive the implant when their dominant follicle reaches a certain size but before the hormone surge that triggers ovulation. Researchers will track hormone levels and ultrasound images to see if ovulation is blocked. If successful, this could offer a longer-acting emergency contraceptive option and simplify birth control access.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Etonogestrel implant
What this could lead to
If it works, this could allow the etonogestrel implant to be used as emergency contraception, simplifying birth control access and reducing the need for extra emergency pills.
What could go wrong
This is a small pilot study with only 12 participants, so results may not apply broadly. The implant may not reliably block ovulation in all cases, and more research would be needed before changing guidelines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI less than or equal to 28kg/m2 * Intact uterus with at least one ovary * Regular menstrual cycles that occur every 21-35 days * If patient is postpartum or post-second trimester abortion, 3 menses (2 cycles) must have occurred prior to enrollment * If patient had a first trimester abortion or pregnancy loss, she must have one spontaneous menses prior to enrollment * Desires insertion of an etonogestrel contraceptive implant for contraception * Not currently pregnant or trying to become pregnant * Willing to abstain from medications and supplements known to induce/inhibit CYP3A4 during the study Exclusion Criteria: * Have a known hypersensitivity or contraindications to etonogestrel. * Medical conditions that affect liver function (e.g., hepatitis, cirrhosis; assessed via participant self-report) * Known or suspected current alcohol dependence syndrome or any illicit drug use that may affect the metabolism of the etonogestrel. * Uncontrolled thyroid disorder. * Use of long-acting injectable hormonal contraceptive within the past 9 months * Current use of hormonal oral, patch, intravaginal, or intrauterine contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contraception are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contraception

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Colorado Denver

    RECRUITING

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.